Biodyne Co. Ltd. (314930) fair value: what the stock is really worth
As of Oct 26, 2026: fair value (intrinsic value) of Biodyne Co. Ltd. stock KRW 636, price KRW 6,050, upside -89.5%, quality 54 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Fair value above price?No
Good quality?Yes
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 26, 2026.
How to read this chart
60‑month range 3,490 KRW – 22,800 KRW · fair‑value band 514.60 KRW – 794.48 KRW · the 6,050 KRW price screens above the 635.59 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 26, 2026.
Follow Biodyne Co. in your weekly email
Every Wednesday you see whether Biodyne Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Biodyne Co., Ltd. engages in the development, manufacture, and sale of liquid-based cytology (LBC) equipment and reagent kits for cancer diagnosis in South Korea.
Show moreShow less
The company offers PATHPLORER solution, which preserves and fixes the collected cells; PATHPLORER LBC system, an equipment for processing liquid cytology samples for cancer diagnosis. It exports its products to Japan, Russia, Portugal, Thailand, and internationally.
The company was founded in 1999 and is headquartered in Seoul, South Korea.
Stock analysis
Biodyne Co. Ltd. (314930) currently trades at 6,050 KRW, while our model-based Fair Value estimate is 635.59 KRW, 89.5% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 932.29 KRW per share, and 0 of the 14 models we run sit above the 6,050 KRW price.
Bear case: the Multiples group reads lowest at 491.14 KRW, and 14 of the 14 models stay below the price. Data coverage for this calculation is low.
Scenario range: 514.60 KRW (bear) to 794.48 KRW (bull), the price of 6,050 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Biodyne Co. Ltd. reported revenue of 7.0B KRW in FY2025 versus 3.8B KRW in FY2021, a compound +16.9%/yr. Reported net income was 852M KRW in FY2025.
Key figures
Market cap 178B KRW (≈ $135M) Micro · P/S ratio 34.9 · Net margin 21.2% · Return on equity 3.3% · Return on assets (EBIT) 0.5% · Operating margin −116% · Revenue (TTM) 5.8B KRW · Revenue growth (YoY) −67.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 63% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −43% fair-value upside, at −89%, 314930 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (156.17 KRW to 6,015 KRW). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear514.60 KRWFair Value 635.59 KRWBull794.48 KRW
Price 6,050 KRW · Upside -89.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+33.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.9%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.3%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−73.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−73.1%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−50% → 9%
⚠ Revenue per share shrinking 26.6%/yr over ~5Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 186 stocks
Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score54 · Below median
Fair Value upside−89.5% · Bottom 25%
Profitability
Return on equity (12 months)3.3% · Below median
Return on assets1.9% · Below median
Net margin (12 months)21.2% · Top 25%
Operating margin (12 months)−115.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−67.2% · Bottom 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/B4.05× · Priciest 25%
P/S (12 months)30.89× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 22
FUTURE (revenue growth)0· sector 36
PAST (return on equity)13· sector 27
HEALTH (low debt)100· sector 96
DIVIDEND (yield)0· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Biodyne Co. Ltd. (314930) overvalued or undervalued?
As of Oct 26, 2026, our model estimates a fair value of 635.59 KRW versus a price of 6,050 KRW, about −89% upside (overvalued).
What is the fair value of 314930?
Our model-based fair value for Biodyne Co. Ltd. is 635.59 KRW (as of Oct 26, 2026), built from audited fundamentals. The current price: 6,050 KRW.
What is the quality score of 314930?
Biodyne Co. Ltd. has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biodyne Co. Ltd. (314930)?
Our model-based price target is the fair value of 635.59 KRW (as of Oct 26, 2026) from 14 valuation models. Cautious scenario 514.60 KRW, optimistic scenario 794.48 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Biodyne Co. Ltd. stock forecast for 2026?
Our models put fair value at 635.59 KRW, about −89% upside versus a price of 6,050 KRW (overvalued). Cautious scenario 514.60 KRW, optimistic scenario 794.48 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Biodyne Co. Ltd. (314930)?
Biodyne Co. Ltd. reported trailing-twelve-month revenue of about 5.8B KRW (latest available figure, as of Oct 26, 2026).
What is the intrinsic value of Biodyne Co. Ltd. (314930)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biodyne Co. Ltd. it is 635.59 KRW per share (as of Oct 26, 2026), against a price of 6,050 KRW. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Biodyne Co. Ltd. stock overvalued or undervalued in 2026?
As of Oct 26, 2026, 314930 trades above its calculated fair value: price 6,050 KRW, fair value 635.59 KRW, a gap of about −89% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 314930?
No. The price is what the market pays today (6,050 KRW); the fair value is what the company's own numbers justify (635.59 KRW). For Biodyne Co. Ltd. the two are 5,414 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Biodyne Co. Ltd. worth?
The market values Biodyne Co. Ltd. at about 178B KRW (market capitalisation, as of Oct 26, 2026). Per share that is 6,050 KRW; our models calculate a fair value of 635.59 KRW per share.
What do the bullish and bearish scenarios say about 314930?
Our models span a range for Biodyne Co. Ltd.: cautious scenario 514.60 KRW, base 635.59 KRW, optimistic 794.48 KRW per share (as of Oct 26, 2026, price 6,050 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Biodyne Co. Ltd. (314930)?
Balance-sheet figures for Biodyne Co. Ltd. (as of Oct 26, 2026): return on equity 3.3%. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is 314930 from its 52-week high?
Biodyne Co. Ltd. trades at 6,050 KRW, about 63% below its 52-week high of 16,310 KRW and 6% above the low of 5,720 KRW (as of Oct 26, 2026). Distance from the high says nothing about value: that is what the fair value of 635.59 KRW is for.
Which stocks are comparable to Biodyne Co. Ltd.?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biodyne Co. Ltd. stock attractive at the current price?
The data as of Oct 26, 2026: price 6,050 KRW, calculated fair value 635.59 KRW (−89%), Quality Score 54/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 314930 calculated?
We run Biodyne Co. Ltd. through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 635.59 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.7 % above its aggregate fair value. Biodyne Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biodyne Co. Ltd. (314930)?
The closing price on Oct 26, 2026 was 6,050 KRW. Our model-based fair value is 635.59 KRW, about −89% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biodyne Co. Ltd. right now?
The price sits above even our optimistic bull case (794.48 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Biodyne Co. Ltd.
How large is the market capitalisation of Biodyne Co. Ltd. (314930)?
The market capitalisation of Biodyne Co. Ltd. is 178B KRW (≈ $135M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Biodyne Co. Ltd. (314930)?
The price-to-sales ratio of Biodyne Co. Ltd. is 34.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Biodyne Co. Ltd. (314930)?
The net margin of Biodyne Co. Ltd. is 21.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Biodyne Co. Ltd. (314930)?
The return on equity (ROE) of Biodyne Co. Ltd. is 3.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Biodyne Co. Ltd. (314930)?
On an EBIT basis the return on assets of Biodyne Co. Ltd. is 0.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biodyne Co. Ltd. (314930)?
The operating margin of Biodyne Co. Ltd. is −116% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Biodyne Co. Ltd. (314930)?
Revenue at Biodyne Co. Ltd. is growing −67.2% versus a year earlier (3y avg −16.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Biodyne Co. Ltd. (314930) generate?
The free cash flow of Biodyne Co. Ltd. is −4.8B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Biodyne Co. Ltd. (314930) carry?
The net debt of Biodyne Co. Ltd. is 3.9B KRW (fiscal year 2020). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Biodyne Co. Ltd. in the live analysis
One click puts Biodyne Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 26, 2026